Based on preclinical data, we designed a phase I/II clinical trial to determine the efficacy and toxicity of doxorubicin followed by paclitaxel in the treatment of advanced breast cancer (either untreated or relapsed after
Ernesto Salzano, MD
Advertisement
Articles by Ernesto Salzano, MD
Advertisement
Latest Updated Articles
- Doxorubicin and Paclitaxel (Sequential Combination) in the Treatment
Published: April 1st 1997 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC
2
FDA Grants Regular Approval to Rucaparib in Metastatic CRPC
3
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
4
All-Oral Elacestrant Combos Offer “Tremendous” Benefits in Breast Cancer
5